Rockefeller Capital Management
GTBP icon

Rockefeller Capital Management’s GT Biopharma GTBP Stock Holding History

Rockefeller Capital Management’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-57
Closed -$1K – 2782
2022
Q4 		$1K Hold
57
– – ﹤0.01% 3688
2022
Q3 		$2K Hold
57
– – ﹤0.01% 3587
2022
Q2 		$5K Hold
57
– – ﹤0.01% 3443
2022
Q1 		$4K Hold
57
– – ﹤0.01% 3410
2021
Q4 		$5K Hold
57
– – ﹤0.01% 3266
2021
Q3 		$11K Hold
57
– – ﹤0.01% 2845
2021
Q2 		$26K Sell
57
-10
-15% -$4.16K ﹤0.01% 2368
2021
Q1 		$13K Buy
+67
New +$11.7K ﹤0.01% 2477

Other funds holding GTBP

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFS
Baskin Financial Services Toronto, Ontario, Canada $1.27B AUM 9.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rockefeller Capital Management's GTBP Position: Q1 2023 in Review

Rockefeller Capital Management sold out of GT Biopharma (GTBP) in Q1 2023, closing a stake of 57 shares — an estimated $1K sold.

Rockefeller Capital Management first reported a position in GTBP in Q1 2021 and held it in 8 quarters. The position peaked at $26K in Q2 2021. 35 funds tracked by Wall St. Rank hold GTBP as of Q1 2023.

  • Rockefeller Capital Management reported no remaining GT Biopharma position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 57 GT Biopharma shares in Q1 2023, an estimated $1K.
  • Rockefeller Capital Management first reported a position in GT Biopharma in Q1 2021 and held it in 8 quarters.
  • Rockefeller Capital Management's GT Biopharma position peaked at $26K in Q2 2021.
  • 35 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.